Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3526318 in healthy females for dermal blood flow
NCT04183283Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing LY3526318 with Placebo (2 arms). Primary endpoint: Decrease in Cinnamaldehyde-Induced Dermal Blood Flow Relative to Placebo Measured by Laser Doppler Imaging at 3 Hours Post-dose. Started Dec 2019; status: completed.
02
Drugs
LY3526318
Beyond the preview
Go deeper on NCT04183283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04183283.